147 related articles for article (PubMed ID: 35752205)
41. Differential in vitro effects of insulin on Taenia crassiceps and Taenia solium cysticerci.
Escobedo G; Romano MC; Morales-Montor J
J Helminthol; 2009 Dec; 83(4):403-12. PubMed ID: 19549345
[TBL] [Abstract][Full Text] [Related]
42. Taenia crassiceps organic acids detected in cysticerci.
Vinaud MC; Lino Rde S; Bezerra JC
Exp Parasitol; 2007 Aug; 116(4):335-9. PubMed ID: 17346707
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of the efficacy of albendazole sulphoxide and praziquantel in combination on Taenia crassiceps cysts: in vitro studies.
Palomares F; Palencia G; Ambrosio JR; Ortiz A; Jung-Cook H
J Antimicrob Chemother; 2006 Mar; 57(3):482-8. PubMed ID: 16410266
[TBL] [Abstract][Full Text] [Related]
44. Understanding the pathogenic mechanisms and therapeutic effects in neurocysticercosis.
Castillo G; Fustamante L; Delgado-Kamiche AD; Camen-Orozco RP; Clark T; Bernal E; Morales-Alvarez J; Ferrufino M; Mamani-Palomino J; Bustos JA; Garcia HH; Gavidia CM; Gilman RH; Verastegui M;
Brain Pathol; 2024 Jan; ():e13237. PubMed ID: 38212958
[TBL] [Abstract][Full Text] [Related]
45. Transcriptome profiling of the cysticercus stage of the laboratory model Taenia crassiceps, strain ORF.
García-Montoya GM; Mesa-Arango JA; Isaza-Agudelo JP; Agudelo-Lopez SP; Cabarcas F; Barrera LF; Alzate JF
Acta Trop; 2016 Feb; 154():50-62. PubMed ID: 26571070
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of neurocysticercosis: a review].
Nogales-Gaete J; Arriagada C; Salinas R
Rev Med Chil; 2006 Jun; 134(6):789-96. PubMed ID: 17130956
[TBL] [Abstract][Full Text] [Related]
47. In vivo treatment with nitazoxanide induces anaerobic metabolism in experimental intraperitoneal cysticercosis.
Nasareth JM; Fraga CM; Lima NF; Picanço GA; Costa TL; Lino-Junior RS; Vinaud MC
Parasitol Res; 2017 Nov; 116(11):3037-3041. PubMed ID: 28914356
[TBL] [Abstract][Full Text] [Related]
48. Effect of Transforming Growth Factor-β upon Taenia solium and Taenia crassiceps Cysticerci.
Adalid-Peralta L; Rosas G; Arce-Sillas A; Bobes RJ; Cárdenas G; Hernández M; Trejo C; Meneses G; Hernández B; Estrada K; Fleury A; Laclette JP; Larralde C; Sciutto E; Fragoso G
Sci Rep; 2017 Sep; 7(1):12345. PubMed ID: 28955045
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of Taenia solium and Taenia crassiceps cysticercal antigens for the serodiagnosis of neurocysticercosis.
Arruda GC; da Silva AD; Quagliato EM; Maretti MA; Rossi CL
Trop Med Int Health; 2005 Oct; 10(10):1005-12. PubMed ID: 16185235
[TBL] [Abstract][Full Text] [Related]
50. Anthelmintics for people with neurocysticercosis.
Monk EJM; Abba K; Ranganathan LN
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD000215. PubMed ID: 34060667
[TBL] [Abstract][Full Text] [Related]
51. Quantitative screening for anticestode drugs based on changes in baseline enzyme secretion by Taenia crassiceps.
Mahanty S; Madrid EM; Nash TE
Antimicrob Agents Chemother; 2013 Feb; 57(2):990-5. PubMed ID: 23229489
[TBL] [Abstract][Full Text] [Related]
52. Medical management of neurocysticercosis.
Takayanagui OM; Odashima NS; Bonato PS; Lima JE; Lanchote VL
Expert Opin Pharmacother; 2011 Dec; 12(18):2845-56. PubMed ID: 22082143
[TBL] [Abstract][Full Text] [Related]
53. Alterations in Taenia crassiceps cysticerci cytoskeleton induced by nitazoxanide and flubendazole.
de Lima NF; Picanço GA; Valencia DGR; Villegas EOL; Mellado MDRE; Ambrosio JR; Vinaud MC
Acta Trop; 2021 Sep; 221():106027. PubMed ID: 34216560
[TBL] [Abstract][Full Text] [Related]
54. Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: a reason for the variable efficacy of albendazole and praziquantel?
Romo ML; Carpio A; Kelvin EA
J Clin Pharmacol; 2014 Apr; 54(4):361-7. PubMed ID: 24443292
[TBL] [Abstract][Full Text] [Related]
55. Anticysticercal treatment and seizures in neurocysticercosis.
Singh G; Sander JW
Lancet Neurol; 2004 Apr; 3(4):207-8. PubMed ID: 15039032
[No Abstract] [Full Text] [Related]
56. Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis.
Garcia HH; Lescano AG; Gonzales I; Bustos JA; Pretell EJ; Horton J; Saavedra H; Gonzalez AE; Gilman RH;
Clin Infect Dis; 2016 Jun; 62(11):1375-9. PubMed ID: 26984901
[TBL] [Abstract][Full Text] [Related]
57. Metabolic effects of anthelminthic drugs in the larval stage of the cestode Taenia crassiceps, cysticercosis experimental model - A review.
Vinaud MC; Ambrosio J
Acta Trop; 2020 Jun; 206():105448. PubMed ID: 32194066
[TBL] [Abstract][Full Text] [Related]
58. Histopathologic aspects of experimental cysticercosis and in situ cytokines profile in C57BL/6 mice.
Milhomem AC; Souza AJS; Silva HM; Vinaud MC; Oliveira MAP; Machado JR; Lino Júnior RS
Arq Neuropsiquiatr; 2018 May; 76(5):339-345. PubMed ID: 29898081
[TBL] [Abstract][Full Text] [Related]
59. Neurocysticercosis: the enigmatic disease.
Agapejev S
Cent Nerv Syst Agents Med Chem; 2011 Dec; 11(4):261-84. PubMed ID: 22300228
[TBL] [Abstract][Full Text] [Related]
60. Demyelination in experimental intraventricular neurocysticercosis.
Moura VBL; Milhomem AC; Lima SB; Matos-Silva H; Sugita DM; Vinaud MC; Lino-Júnior RS
Arq Neuropsiquiatr; 2020 Feb; 78(2):103-111. PubMed ID: 32022135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
